Abstract In sub-Saharan Africa, simple biomarkers of liver fibrosis are needed to scale-up
hepatitis B treatment. We conducted an individual participant data meta-analysis of 3,548 …

More than 80% of global hepatocellular carcinoma (HCC) patients are estimated to occur in
sub-Saharan Africa (SSA) and Eastern Asia. The most common risk factor of HCC in SSA is …

Methods A retrospective cohort of 674 patients with chronic hepatitis B virus (HBV) infection
who received antiviral treatment for more than 12 months was analyzed for the development …

Progress towards hepatitis B virus (HBV) elimination targets remains slow, despite efforts to
support enhanced prevention, diagnosis and treatment. On the basis of insights from …

There are 82 million people living with hepatitis B (PLWHB) in the World Health
Organization Africa region, where it is the main cause of liver disease. Effective vaccines …

Background & Aims In 2015, the World Health Organization (WHO) issued guidelines for the
management of chronic hepatitis B (CHB) in low-and middle-income countries, but little is …

Chronic hepatitis B virus disproportionately affects migrant communities in high-income
countries, reflecting increased migration from sub-Saharan Africa. Chronic hepatitis B virus …

Despite a high prevalence, there are few successful models for de‐centralizing diagnosis
and treatment of chronic hepatitis B virus (HBV) infection among rural communities in Sub …

BACKGROUND Chronic hepatitis B (CHB) virus infection is a major cause of liver-
associated morbidity and mortality, particularly in low-income countries. A better …

Individuals with chronic hepatitis B virus (HBV) infection who are at substantial risk of HIV
acquisition benefit from pre-exposure prophylaxis (PrEP) with tenofovir-based antiviral …